The reclassification of cannabis to a less restrictive schedule of the US Controlled Substances Act will have crucial implications for the industry, especially as far as taxation is concerned, experts say.
News that the Drug Enforcement Administration (DEA) had agreed with the Department of Health and Human Services (HHS) to recommend moving cannabis from Schedule I to Schedule III of the act was leaked by US press at the end of April, paving the way for speculation over its economic impact for the sector.